

Schrödinger announces expanded collaboration with AstraZeneca

24 March 2020 | News

It focuses on the further development of a modeling solution for biologicals



Schrödinger, operator of a physics-based software platform for the discovery of high-quality, novel molecules for therapeutics and materials, has announced an expanded collaboration with AstraZeneca.

It focuses on the further development of a modeling solution for biologicals in order to accelerate the development of therapeutic candidates based on antibodies and proteins.

The multi-year agreement will continue the existing collaboration in which AstraZeneca is driving research into small-molecule drugs with Schrödinger's computer platform.

The new collaboration aims to improve Schrödinger's Free Energy Perturbation (FEP+) technology to optimize key properties of biologicals such as affinity and selectivity, with a particular focus on binding affinity.